The DTNBP1 Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A2780 human ovarian carcinoma cell line, featuring targeted disruption of the DTNBP1 gene. This polyclonal format consists of a heterogeneous mix of edited alleles, providing a representative loss-of-function system for studying dysbindin biology. The CRISPR/Cas9-mediated gene disruption ensures that key DTNBP1-controlled pathways are abrogated across the cell population, enabling robust functional analyses.
The A2780 host cells represent an established epithelial ovarian cancer model, originally isolated from an untreated patient tumor and characterized by cisplatin sensitivity and wild-type TP53 status. These adherent cells maintain hallmark ovarian carcinoma properties, including rapid proliferation and susceptibility to platinum-based chemotherapeutics, making them a standard platform for cancer cell biology and drug resistance investigations.
DTNBP1 encodes dysbindin, a core subunit of the BLOC-1 complex that orchestrates lysosome-related organelle biogenesis. DTNBP1 interacts extensively with BLOC-1 partners BLOC1S1?C6 and SNAPIN, as well as with dystrobrevin, AP-3, and WASH complexes. Its activity is transcriptionally induced by CREB1 and BDNF/TrkB signaling, while it governs downstream targets such as VAMP7, Rab32/38, tyrosinase, and dopamine receptor D2. Disruption of DTNBP1 impairs intracellular vesicle trafficking, melanosome formation, and neurotransmitter receptor cycling, thus affecting diverse cellular processes.
In the context of A2780 ovarian carcinoma, DTNBP1 knockout potentially influences lysosomal dynamics, autophagy, and exosome secretion, all of which intersect with drug response mechanisms. Loss of DTNBP1 may modulate the trafficking of membrane proteins, including those involved in cisplatin uptake or efflux, offering a unique model to explore BLOC-1 contributions to chemoresistance and tumor cell migration, as cytoskeletal remodeling via the WASH complex is also affected.
Research applications of these polyclonal knockout cells encompass investigation of BLOC-1 function in ovarian cancer biology, modeling of Hermansky-Pudlak syndrome-related trafficking defects, and neuronal disorder studies due to DTNBP1??s synaptic roles. The cells are amenable to Western blotting, RT-qPCR, immunofluorescence, LysoTracker staining, flow cytometry, and functional assays such as migration/invasion and cisplatin sensitivity. Both cancer biologists and neuroscientists will find this model valuable. For further details, contact Ascent Research.
